A new drug has been found to reduce memory decline among patients with early-stage Alzheimer’s in a “historic breakthrough” in treating the disease. Results have been reported by Eisai, a Tokyo-based pharmaceutical company that has partnered with U.S. biotech firm Biogen to develop lecanemab. The question is will HCPs trust Biogen?